Q4 2025 BioMarin Pharmaceutical Inc Earnings Call Transcript

Feb 23, 2026 / 09:30PM GMT

Release Date Price: $62.92 (-1.81%)

Transcript 10-K8-K

Key Points

Positve

BioMarin Pharmaceutical Inc (BMRN) achieved a 13% increase in total revenues for 2025, reaching a record $3.22 billion.
Voxzogo revenues rose by a remarkable 26%, demonstrating strong global expansion and market penetration.
The company successfully completed strategic acquisitions, including Inozyme and Amicus, to enhance its enzyme therapies portfolio and expand its commercial reach.
BioMarin anticipates high single-digit growth in enzyme therapies and Voxzogo in 2026, with Voxzogo on track to achieve blockbuster status.
The company is preparing to initiate a Phase II/III study of BMN 333, a next-generation, long-acting CNP therapy, which could set a new standard of care for achondroplasia.

Negative

BioMarin Pharmaceutical Inc (BMRN) recorded approximately $240 million in special items related to the strategic decision to withdraw Roctavian from the market.
The company expects significantly lower royalty revenues from KUVAN and Roctavian in 2026, posing a 3% headwind to total revenue growth.
BioMarin faces potential competitive pressures in the achondroplasia market with the emergence of oral therapies.
The company anticipates routine market access renegotiations in 2026, which could impact pricing and revenue dynamics.
BioMarin's guidance for 2026 reflects potential challenges, including integration costs and interest expenses related to the Amicus acquisition, which may slightly dilute operating margins.

Operator

Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceutical fourth quarter and full year 2025 conference call. (Operator Instructions) I would now like to turn the call over to Traci McCarty, Head of Investor Relations. Please go ahead.

Traci McCarty

BioMarin Pharmaceutical Inc - Vice President & Head of Investor Relations

Thank you, operator. And starting on slide 2. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.

Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.